Clinical Trials Browser

Ovarian Neoplasms × Ipilimumab × 90 days × Clear all

Neoplasm Metastasis, Ovarian Neoplasms

NCT03355976 2026-04-02

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Phase 2 Active not recruiting

46 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence, Adenocarcinoma, Clear Cell

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Phase 1 Active not recruiting

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Clinical Trials

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer